Alto Neuroscience Accelerates Development of ALTO-207
In a significant advancement for the treatment of treatment-resistant depression (TRD), Alto Neuroscience, Inc. has announced its intention to expedite the development of ALTO-207. This decision follows a constructive meeting with the U.S. Food and Drug Administration (FDA), where the company received positive feedback on its development plans. The company is set to utilize proceeds from a recently secured $50 million private placement to fund this initiative, which includes preparations for a Phase 3 clinical trial expected to commence in early 2027.
The chief executive officer of Alto Neuroscience, Amit Etkin, M.D., Ph.D., emphasized the importance of the recent FDA meeting, highlighting it as a pivotal moment for the company’s efforts to bring ALTO-207 to patients who currently lack effective treatment options. He noted that the new financing will provide the necessary resources to accelerate the pathway to critical studies and potential market approval.
Milestones and Future Projections
Alto Neuroscience is gearing up to initiate a Phase 2b clinical trial for ALTO-207 by mid-2026. This trial is anticipated to be pivotal, as it aligns with discussions held with the FDA regarding study design and protocol. Following these preparations, the company expects to launch a Phase 3 trial by early 2027.
In addition to ALTO-207, Alto is also making strides with other candidates in its pipeline, specifically ALTO-100 and ALTO-101. Positive outcomes from blinded pharmacokinetic (PK) analyses have underscored the efficacy of these treatments, with compliance rates significantly exceeding norms seen in similar central nervous system trials. These results suggest an enhanced patient tolerability and engagement with treatment regimens.
The Composition and Purpose of ALTO-207
ALTO-207 is a unique fixed-dose combination therapy that includes pramipexole, which is primarily used to treat Parkinson’s disease and has shown antidepressant properties, along with ondansetron, a well-known antiemetic. This innovative combination aims to provide a rapid titration and higher dosing capabilities, which can mitigate the adverse events typically associated with pramipexole, thus responding to the unmet needs of TRD patients.
In a prior randomized, placebo-controlled Phase 2a trial involving 32 patients, ALTO-207 successfully met both primary and secondary endpoints, demonstrating significant improvements in depression scores compared to the placebo group. The treatment was well tolerated during the maintenance phase, exhibiting an adverse event profile comparable to that of placebo.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical entity dedicated to transforming the landscape of psychiatric treatment through innovative, precision medicine. The company’s Precision Psychiatry Platform™ integrates advanced techniques such as EEG analysis and cognitive assessments to tailor therapies based on individual patient responses. Alto’s pipeline focuses on various mental health conditions, including bipolar depression and schizophrenia, aiming to provide more effective and personalized treatment solutions. For further details, visit their official website at www.altoneuroscience.com or connect with them on social media platforms.
With these strategic developments, Alto Neuroscience is poised to make significant strides in addressing treatment-resistant depression, potentially improving outcomes for countless individuals seeking relief from this debilitating condition.
Related
